Santos (ASX:STO), the mammoth gas producer, tumbled by 5% and dragged down the sector after its full-year profit slumped 14%, ...
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results